SCHEMBL6491121

SCHEMBL6491121

NS(=O)(=O)C=Cc1ccncc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 7/20 0.51
JUN P05412 1/20 0.47
NFKB1 P19838 1/20 0.47
NPC1 O15118 4/20 0.41
MAPT P10636 3/20 0.41
RAB9A P51151 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
ALOX5 P09917 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 2/20 0.40
KDM1A O60341 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
HBB P68871 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491117 1.00 NFE2L2 (0.51) NFE2L2JUNNFKB1NPC1MAPT
SCHEMBL27236304 0.78 NFE2L2 (0.53) NFE2L2JUNNFKB1NPC1MAPT
SCHEMBL359805 0.77 PPARG (0.53) NFE2L2KMT2APTGS1PTGS2
SCHEMBL1205879 0.77 PPARG (0.53) NFE2L2KMT2APTGS1PTGS2
SCHEMBL4260845 0.76 NFE2L2 (0.58) NFE2L2JUNNFKB1NPC1MAPT
SCHEMBL4260836 0.76 NFE2L2 (0.58) NFE2L2JUNNFKB1NPC1MAPT
SCHEMBL5766149 0.76 PPARG (0.52) NFE2L2KMT2APTGS1PTGS2
SCHEMBL5766143 0.76 PPARG (0.52) NFE2L2KMT2APTGS1PTGS2
SCHEMBL10641465 0.76 CYP19A1 (0.52) CYP3A4CYP2C9PTGS1PTGS2CA1
SCHEMBL10641470 0.76 CYP19A1 (0.52) CYP3A4CYP2C9PTGS1PTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A NFE2L2 4146/4885JUN 4509/4885NFKB1 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.